| bortezomib / Generic mfg. |
NCT00027716: Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma |
|
|
| Completed | 2 | | US | bortezomib | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Sarcoma | 05/04 | 05/04 | | |
NCT00611325: Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma |
|
|
| Completed | 2 | 56 | US | Avastin, Bevacizumab, Bortezomib, Velcade | Duke University, Millennium Pharmaceuticals, Inc., Genentech, Inc. | Glioblastoma, Gliosarcoma | 09/09 | 10/13 | | |
NCT00641706: Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme |
|
|
| Completed | 2 | 44 | US | vorinostat, L-001079038, SAHA, suberoylanilide hydroxamic acid, Zolinza, therapeutic conventional surgery, bortezomib, LDP 341, MLN341, VELCADE | National Cancer Institute (NCI) | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor | 07/10 | 11/10 | | |
NCT00937495: Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma |
|
|
| Completed | 2 | 16 | US | vorinostat, L-001079038, SAHA, suberoylanilide hydroxamic acid, Zolinza, bortezomib, LDP 341, MLN341, VELCADE | National Cancer Institute (NCI) | Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma | 08/10 | 06/11 | | |
NCT00998010: Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma |
|
|
| Completed | 2 | 24 | US | bortezomib + temozolomide+ radiation therapy | Jonsson Comprehensive Cancer Center, Millennium Pharmaceuticals, Inc. | Brain and Central Nervous System Tumors | 03/16 | 04/18 | | |
